CARDOXIN FORTE

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

DIPYRIDAMOLE

متاح من:

RAFA LABORATORIES LTD

ATC رمز:

B01AC07

الشكل الصيدلاني:

TABLETS

تركيب:

DIPYRIDAMOLE 75 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

RAFA LABORATORIES LTD, JERUSALEM

المجموعة العلاجية:

DIPYRIDAMOLE

المجال العلاجي:

DIPYRIDAMOLE

الخصائص العلاجية:

As an adjunct to oral anticoagulants for prophylaxis of thromboembolism associated with prosthetic heart valves. Reduction of proteinuria in the nephrotis syndrome. Treatment of membranoproliferative glomerulonephritis. Prevention of pre-eclampsia in the final trimester of pregnancy. Prevention of transplant artery stenosis. Prevention of post-operative thromboembolic complications of coronary artery surgery. In combination with acetylsalicylic acid in cases of recurrent deep vein thrombosis resistant to oral anticoagulants. Prevention of thrombogenic manifestations. As an alternative to exercise stress in thallium myocardial imaging particularly in patients unable to exercise or in those for whom exercise may be contraindicated.

تاريخ الترخيص:

2012-06-30

نشرة المعلومات

רישכתה םש
הטרופ ןיסכודראק
אפר ט"קמ
194012
הרודהמ 'סמ
012004-
I
הסירפ
)2( 'ג / 3 חפסנ יפל מ"ס
16X25
עבצ
רוחש
תופש
)תיברעו תילגנא ,תירבע( 3
סופד
לאידיא
םילופיק 'סמ
0
:לופיק רחאל יפוס לדוג
מ"מ
24.5X16
ריינ גוס
םרג 60
דוקהמרפ
)תולע אלל דוקמרפה תא שיבלי סופדה תיב( 637
דוקהמרפ יוקל תודימ
;מ"מ 1 םיווקה ןיב חוור ;מ"מ 1.5 הבע וק ;מ"מ
0.5 קד וק
תופידע - מ"מ 8 םומינימ( מ"מ 10 םומיסקמ וטנ
ךרוא
)תילמיסקמ הדימל
י"ע ןכוה
םייטבצמרפ םיתוריש ואלב
ךיראת
21.06.2012
:ةعرلجا
.عضرلاو لافطلأل ماع لكشب صصمخ يرغ
ءاودلا اذه
.اهب ىصولما ةعرلجا زواتج زويج لا .طقف
بيبطلا تاميلعتل ا
ً
قفو ةعرلجا
بيبطلا لبق نم د
ّ
دح ام بسبح ةددمح تاقوأب ءاودلا اذه
لامعتسا بيج
.لجاعلما
.كركذت روف ةعرج لوانت بيج ددلمحا تقولا
في ءاودلا اذه لوانت تيسن اذإ
ا
ً
عطق زويج لا .ةيسنلما ةعرلجا ىطتخ
,ةيلاتلا ةعرلجا لوانتل تقولا ناح اذإ
!اعم ينتعرج لوانت
:لامعتسلاا ةيفيك
.ءام سأك عم ءاودلا علب بيج !صرقلا قحس وأ
غضم زويج لا
.ةبجولا لبق ءاودلا لوانتب ىصوي
.هعلبل ةمزللا ة
ّ
د
ُ
لما نم رثكأ مفلا في ءاودلا ءاقبإ زويج
لا
.فيصنت طخ دوجو مدعل كلذو صرقلا رطش زويج
لا
؟جلاعلا حاجنب ةمهاسلما كنكيم فيك
.بيبطلا لبق نم هب ىصولما جلعلا لامكإ
كيلع
نستح أرط ولو تىح بيبطلا ةراشتسا نودب
ءاودلاب جلعلا نع فقوتت لا
.ةيحصلا كتلاح ىلع
!ممستلا بنتج
يديأ �

خصائص المنتج

CARDOXIN FORTE-DL-June 2012-02
DOCTOR LEAFLET
CARDOXIN FORTE
TABLETS
COMPOSITION
Active ingredient: each tablet contains: dipyridamole 75 mg
Inactive ingredients: Starch corn, silicon dioxide colloidal 200,
starch soluble, magnesium stearate,
calcium phosphate dibasic anhydrous, lactose monohydrate,
hydroxypropylmethylcellulose,
titanium dioxide, macrogol 4000, sunset yellow 85 (E110).
Each tablet contains approx. 2 mg lactose.
ACTION
Dipyridamole increases coronary blood flow and coronary sinus oxygen
saturation. It appears to
act predominantly on the small resistance vessels of the coronary
vascular bed. The coronary
vasodilator effect of dipyridamole is probably due to its ability to
inhibit adenosine deaminase in
the blood, thus allowing the accumulation of adenosine, a potent
vasodilator. It may also cause
vasodilation by inhibiting the enzyme phosphodiesterase, thus delaying
the hydrolysis of cyclic
adenosine monophosphate (cAMP).
In vitro models, induced-thrombotic animal models and several clinical
studies have shown that
the prophylactic administration of the proper dose of dipyridamole
can, in many cases, reduce the
number of thromboembolic episodes. This is based on its ability to
prevent platelet adhesion and
aggregation, thus prolonging platelet survival time.
It is postulated that dipyridamole acts by enhancing prostacyclin
effects or inhibiting
phosphodiesterase, thus increasing adenyl cyclase formation. It has
also been shown to inhibit
the formation of thromboxane-A
2
, which is known to cause platelet adhesion and aggregation.
INDICATIONS
As an adjunct to oral anticoagulants for prophylaxis of
thromboembolism associated with
prosthetic heart valves.
Reduction of proteinuria in the nephrotic syndrome.
Treatment of membranoproliferative glomerulonephritis.
Prevention of pre-eclampsia in the final trimester of pregnancy.
Prevention of transplant artery stenosis.
Prevention of post-operative thromboembolic complications of coronary
artery surgery.
In combination with acetylsalicylic acid in cases of